220 related articles for article (PubMed ID: 28130839)
1. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour.
Schaefer IM; Hornick JL; Sholl LM; Quade BJ; Nucci MR; Parra-Herran C
Histopathology; 2017 Jun; 70(7):1138-1146. PubMed ID: 28130839
[TBL] [Abstract][Full Text] [Related]
2. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
Chen L; Yang B
Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
[TBL] [Abstract][Full Text] [Related]
4. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
[TBL] [Abstract][Full Text] [Related]
5. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus).
Sprogøe-Jakobsen S; Hølund B
APMIS; 1996 Oct; 104(10):705-8. PubMed ID: 8980620
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory Myofibroblastic Tumor of the Uterus: An Immunohistochemical Study of 23 Cases.
Bennett JA; Croce S; Pesci A; Niu N; Van de Vijver K; Burks EJ; Burandt E; Zannoni GF; Rabban JT; Oliva E
Am J Surg Pathol; 2020 Nov; 44(11):1441-1449. PubMed ID: 32568825
[TBL] [Abstract][Full Text] [Related]
8. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma.
Liang Y; Zhang X; Chen X; Lü W
Int J Clin Exp Pathol; 2015; 8(6):7196-202. PubMed ID: 26261614
[TBL] [Abstract][Full Text] [Related]
10. Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors.
Arias-Stella JA; Benayed R; Oliva E; Young RH; Hoang LN; Lee CH; Jungbluth AA; Frosina D; Soslow RA; Antonescu CR; Ladanyi M; Chiang S
Am J Surg Pathol; 2019 Mar; 43(3):382-388. PubMed ID: 30489320
[TBL] [Abstract][Full Text] [Related]
11. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors.
Ptáková N; Miesbauerová M; Kosťun J; Grossmann P; Šidlová H; Pavelka J; Presl J; Alaghehbandan R; Bouda J; Ondič O
Virchows Arch; 2018 Nov; 473(5):583-590. PubMed ID: 30116888
[TBL] [Abstract][Full Text] [Related]
13. Myxoid Leiomyosarcoma of the Uterus: A Clinicopathologic Analysis of 30 Cases and Review of the Literature With Reappraisal of Its Distinction From Other Uterine Myxoid Mesenchymal Neoplasms.
Parra-Herran C; Schoolmeester JK; Yuan L; Dal Cin P; Fletcher CD; Quade BJ; Nucci MR
Am J Surg Pathol; 2016 Mar; 40(3):285-301. PubMed ID: 26866354
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory myofibroblastic tumor of the uterus - case report.
Štiková Z; Ptáková N; Horáková M; Kosťun J; Ondič O
Cesk Patol; 2019; 55(4):239-243. PubMed ID: 31842556
[TBL] [Abstract][Full Text] [Related]
15. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
[TBL] [Abstract][Full Text] [Related]
16. Myxoid Mesenchymal Tumors of the Uterus: An Update on Classification, Definitions, and Differential Diagnosis.
Busca A; Parra-Herran C
Adv Anat Pathol; 2017 Nov; 24(6):354-361. PubMed ID: 28787279
[TBL] [Abstract][Full Text] [Related]
17. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
18. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.
Fernandez-Flores A; Monteagudo C
Ann Diagn Pathol; 2016 Oct; 24():25-9. PubMed ID: 27649950
[TBL] [Abstract][Full Text] [Related]
19. Loss of CDKN2A Promoter Methylation Coincides With the Epigenetic Transdifferentiation of Uterine Myosarcomatous Cells.
Roncati L; Barbolini G; Sartori G; Siopis E; Pusiol T; Maiorana A
Int J Gynecol Pathol; 2016 Jul; 35(4):309-15. PubMed ID: 27276112
[TBL] [Abstract][Full Text] [Related]
20. Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma.
Cornejo K; Shi M; Jiang Z
Hum Pathol; 2012 Oct; 43(10):1567-72. PubMed ID: 22497850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]